Olmesartan medoxomil: current status of its use in monotherapy
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeksrsquo; treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resista...
Felodipine-induced eruptive telangiectasia following mastectomy and radiotherapy
(Source: British Journal of Dermatology)div id=medwormpbiMedWorm Message:/i/b Find the best a href=http://www.januarysales.org/ target=_blankJanuary Sales/a in the UK./p/div
